Drug Profile
Research programme: chronic obstructive pulmonary disease therapy - CereMedix
Latest Information Update: 12 Jul 2007
Price :
$50
*
At a glance
- Originator CereMedix
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 01 Jul 2004 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)